Vijay S Ganesh,Kevin Riquin,Nicolas Chatron,Esther Yoon,Kay-Marie Lamar,Miriam C Aziz,Pauline Monin,Melanie C O'Leary,Julia K Goodrich,Kiran V Garimella,Eleina England,Ben Weisburd,François Aguet,Carlos A Bacino,David R Murdock,Hongzheng Dai,Jill A Rosenfeld,Lisa T Emrick,Shamika Ketkar,Yael Sarusi,Damien Sanlaville,Saima Kayani,Brian Broadbent,Alisée Pengam,Bertrand Isidor,Stéphane Bezieau,Benjamin Cogné,Daniel G MacArthur,Igor Ulitsky,Gemma L Carvill,Anne O'Donnell-Luria
{"title":"Neurodevelopmental Disorder Caused by Deletion of CHASERR, a lncRNA Gene.","authors":"Vijay S Ganesh,Kevin Riquin,Nicolas Chatron,Esther Yoon,Kay-Marie Lamar,Miriam C Aziz,Pauline Monin,Melanie C O'Leary,Julia K Goodrich,Kiran V Garimella,Eleina England,Ben Weisburd,François Aguet,Carlos A Bacino,David R Murdock,Hongzheng Dai,Jill A Rosenfeld,Lisa T Emrick,Shamika Ketkar,Yael Sarusi,Damien Sanlaville,Saima Kayani,Brian Broadbent,Alisée Pengam,Bertrand Isidor,Stéphane Bezieau,Benjamin Cogné,Daniel G MacArthur,Igor Ulitsky,Gemma L Carvill,Anne O'Donnell-Luria","doi":"10.1056/nejmoa2400718","DOIUrl":null,"url":null,"abstract":"CHASERR encodes a human long noncoding RNA (lncRNA) adjacent to CHD2, a coding gene in which de novo loss-of-function variants cause developmental and epileptic encephalopathy. Here, we report our findings in three unrelated children with a syndromic, early-onset neurodevelopmental disorder, each of whom had a de novo deletion in the CHASERR locus. The children had severe encephalopathy, shared facial dysmorphisms, cortical atrophy, and cerebral hypomyelination - a phenotype that is distinct from the phenotypes of patients with CHD2 haploinsufficiency. We found that the CHASERR deletion results in increased CHD2 protein abundance in patient-derived cell lines and increased expression of the CHD2 transcript in cis. These findings indicate that CHD2 has bidirectional dosage sensitivity in human disease, and we recommend that other lncRNA-encoding genes be evaluated, particularly those upstream of genes associated with mendelian disorders. (Funded by the National Human Genome Research Institute and others.).","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmoa2400718","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
CHASERR encodes a human long noncoding RNA (lncRNA) adjacent to CHD2, a coding gene in which de novo loss-of-function variants cause developmental and epileptic encephalopathy. Here, we report our findings in three unrelated children with a syndromic, early-onset neurodevelopmental disorder, each of whom had a de novo deletion in the CHASERR locus. The children had severe encephalopathy, shared facial dysmorphisms, cortical atrophy, and cerebral hypomyelination - a phenotype that is distinct from the phenotypes of patients with CHD2 haploinsufficiency. We found that the CHASERR deletion results in increased CHD2 protein abundance in patient-derived cell lines and increased expression of the CHD2 transcript in cis. These findings indicate that CHD2 has bidirectional dosage sensitivity in human disease, and we recommend that other lncRNA-encoding genes be evaluated, particularly those upstream of genes associated with mendelian disorders. (Funded by the National Human Genome Research Institute and others.).
期刊介绍:
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.